AU2003243228B2 - EphA2 monoclonal antibodies and methods of use thereof - Google Patents

EphA2 monoclonal antibodies and methods of use thereof Download PDF

Info

Publication number
AU2003243228B2
AU2003243228B2 AU2003243228A AU2003243228A AU2003243228B2 AU 2003243228 B2 AU2003243228 B2 AU 2003243228B2 AU 2003243228 A AU2003243228 A AU 2003243228A AU 2003243228 A AU2003243228 A AU 2003243228A AU 2003243228 B2 AU2003243228 B2 AU 2003243228B2
Authority
AU
Australia
Prior art keywords
seq
amino acid
acid sequence
epha2
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003243228A
Other languages
English (en)
Other versions
AU2003243228A1 (en
Inventor
Kelly Carles-Kinch
Peter Kiener
Michael S. Kinch
Solomon Langermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of AU2003243228A1 publication Critical patent/AU2003243228A1/en
Assigned to MEDIMMUNE, LLC reassignment MEDIMMUNE, LLC Alteration of Name(s) of Applicant(s) under S113 Assignors: MEDIMMUNE, INC.
Application granted granted Critical
Publication of AU2003243228B2 publication Critical patent/AU2003243228B2/en
Priority to AU2009202542A priority Critical patent/AU2009202542A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003243228A 2002-05-10 2003-05-12 EphA2 monoclonal antibodies and methods of use thereof Ceased AU2003243228B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2009202542A AU2009202542A1 (en) 2002-05-10 2009-06-25 EphA2 monoclonal antibodies and methods of use thereof

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US37932202P 2002-05-10 2002-05-10
US60/379,322 2002-05-10
US41821302P 2002-10-14 2002-10-14
US60/418,213 2002-10-14
US46050703P 2003-04-03 2003-04-03
US60/460,507 2003-04-03
PCT/US2003/015044 WO2003094859A2 (en) 2002-05-10 2003-05-12 Epha2 monoclonal antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2009202542A Division AU2009202542A1 (en) 2002-05-10 2009-06-25 EphA2 monoclonal antibodies and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2003243228A1 AU2003243228A1 (en) 2003-11-11
AU2003243228B2 true AU2003243228B2 (en) 2009-03-26

Family

ID=29424523

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003243228A Ceased AU2003243228B2 (en) 2002-05-10 2003-05-12 EphA2 monoclonal antibodies and methods of use thereof
AU2009202542A Abandoned AU2009202542A1 (en) 2002-05-10 2009-06-25 EphA2 monoclonal antibodies and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2009202542A Abandoned AU2009202542A1 (en) 2002-05-10 2009-06-25 EphA2 monoclonal antibodies and methods of use thereof

Country Status (8)

Country Link
US (3) US20040028685A1 (OSRAM)
EP (1) EP1519956B1 (OSRAM)
JP (2) JP4557714B2 (OSRAM)
AT (1) ATE525398T1 (OSRAM)
AU (2) AU2003243228B2 (OSRAM)
CA (1) CA2485373A1 (OSRAM)
ES (1) ES2373715T3 (OSRAM)
WO (1) WO2003094859A2 (OSRAM)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US7192698B1 (en) * 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
EP1575509B1 (en) * 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
WO2003094859A2 (en) * 2002-05-10 2003-11-20 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
CA2486615A1 (en) * 2002-05-23 2003-12-04 Purdue Research Foundation Low molecular weight protein tyrosine phosphatase (lmw-ptp) as a diagnostic and therapeutic target
CA2518898A1 (en) 2003-03-12 2004-09-23 Vasgene Therapeutics, Inc. Nucleic acid compounds for inhibiting angiogenesis and tumor growth
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
WO2004092343A2 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Epha2, hypoproliferative cell disorders and epithelial and endothelial reconstitution
JP2006524693A (ja) * 2003-04-11 2006-11-02 メディミューン，インコーポレーテッド ＥｐｈＡ２および非腫瘍性過増殖性細胞障害
JP4764818B2 (ja) * 2003-04-11 2011-09-07 メディミューン，エルエルシー 組換えｉｌ−９抗体およびその使用
JP4838720B2 (ja) * 2003-05-13 2011-12-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 転移および転移がもたらす骨格関連現象を調節する方法
US20050147593A1 (en) * 2003-05-22 2005-07-07 Medimmune, Inc. EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders
WO2005048917A2 (en) 2003-06-06 2005-06-02 Medimmune, Inc. Use of epha4 and modulator or epha4 for diagnosis, treatment and prevention of cancer
EP2371835A1 (en) * 2003-07-03 2011-10-05 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
CA2537055A1 (en) * 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
CN1905899B (zh) * 2003-11-20 2011-09-28 医学免疫公司 EphA2激动性单克隆抗体及其使用方法
WO2005056766A2 (en) * 2003-12-04 2005-06-23 Medimmune, Inc. TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES
US20050153923A1 (en) * 2003-12-04 2005-07-14 Kinch Michael S. Targeted drug delivery using EphA2 or EphA4 binding moieties
WO2005067460A2 (en) * 2003-12-24 2005-07-28 Medimmune, Inc. Epha2 vaccines
DE102004010050A1 (de) * 2004-03-02 2005-09-22 Bayer Healthcare Ag Spezifische monoklonale und polyklonale Antikörper für Repinotan und dessen ringoffene Form
CA2559554A1 (en) 2004-03-12 2005-09-29 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
KR20120123619A (ko) 2004-03-12 2012-11-08 바스진 테라퓨틱스, 인크. 혈관형성 및 종양 성장을 억제하기 위한 폴리펩티드 화합물
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20100173864A1 (en) * 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
AU2005228410A1 (en) 2004-03-29 2005-10-13 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20100028339A1 (en) * 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
JP4879884B2 (ja) 2004-04-12 2012-02-22 メディミューン，エルエルシー 抗−ｉｌ−９抗体製剤及びその使用法
EP1773391A4 (en) * 2004-06-25 2009-01-21 Medimmune Inc INCREASING THE PRODUCTION OF RECOMBINANT ANTIBODIES IN MAMMALIAN CELLS BY MUTAGENESIS ON THE SITE
EP1778726A4 (en) 2004-08-16 2009-03-18 Medimmune Inc INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY
WO2006034455A2 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
US20060121053A1 (en) * 2004-10-18 2006-06-08 Pamela Sweeney High cell density process for growth of Listeria
AU2005299767A1 (en) * 2004-10-21 2006-05-04 The Penn State Research Foundation Eph receptor tumor biomarkers
EP1812077A4 (en) * 2004-10-27 2009-12-02 Medimmune Inc MODULATORS OF EPHA2 AND EPHRINA1 FOR TREATING A FIBROSIS-ASSOCIATED DISEASE
AU2005299355A1 (en) 2004-10-27 2006-05-04 Medimmune, Llc Modulation of antibody specificity by tailoring the affinity to cognate antigens
JP2008518021A (ja) * 2004-10-27 2008-05-29 メディミューン，インコーポレーテッド 感染の治療および予防のためのｅｐｈａ２およびｅｐｈｒｉｎａ１のモジュレーターの使用
KR101363252B1 (ko) * 2005-02-04 2014-02-13 레이븐 바이오테크놀로지스, 인코퍼레이티드 Ｅｐｈａ2에 결합하는 항체 및 그것의 사용방법
JP2008536874A (ja) * 2005-04-15 2008-09-11 ボード オブ リージェンツ ザ ユニバーシティー オブ テキサス システム 中性脂質組成物によるｓｉＲＮＡの送達
JP2008546805A (ja) 2005-06-23 2008-12-25 メディミューン，エルエルシー 最適な凝集および断片化プロフィールを有する抗体製剤
CN101228181B (zh) * 2005-07-20 2013-09-18 默沙东公司 Hcv ns3蛋白酶抑制剂
CA2621502A1 (en) * 2005-09-07 2007-03-15 Medimmune, Inc. Toxin conjugated eph receptor antibodies
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
US7803364B2 (en) * 2005-11-17 2010-09-28 The Cleveland Clinic Foundation Multipotent neural stem cells
EP1968998A4 (en) * 2005-12-21 2010-01-27 Medimmune Llc AFFINITY-OPTIMIZED EPHA2-AGONISTIC ANTIBODIES AND METHODS FOR THEIR USE
ES2673822T3 (es) * 2006-07-18 2018-06-25 Sanofi Anticuerpo antagonista contra EphA2 para el tratamiento de cáncer
CN101918844A (zh) * 2007-06-18 2010-12-15 米迪缪尼有限公司 表达epha2和erbb2的细胞的协同治疗
WO2009151717A2 (en) 2008-04-02 2009-12-17 Macrogenics, Inc. Bcr-complex-specific antibodies and methods of using same
EP2724727A1 (en) 2007-06-27 2014-04-30 The United States of America, as Represented by The Secretary, Department of Health and Human Services Complexes of IL-15 and IL-15R alpha and uses thereof
EP2185594B1 (en) 2007-08-13 2016-04-06 VasGene Therapeutics, Inc. Cancer treatment using humanized antibodies that bind to ephb4
WO2009028639A1 (ja) * 2007-08-30 2009-03-05 Daiichi Sankyo Company, Limited 抗ｅｐｈａ２抗体
CA2759792A1 (en) 2009-04-29 2010-11-04 Trellis Bioscience, Inc. Improved antibodies immunoreactive with heregulin-coupled her3
US8840889B2 (en) 2009-08-13 2014-09-23 The Johns Hopkins University Methods of modulating immune function
AR078470A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis Anticuerpos que se unen especificamente al receptor epha2
CA2776385C (en) 2009-10-07 2019-04-09 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
CN103237901B (zh) 2010-03-01 2016-08-03 卡里斯生命科学瑞士控股有限责任公司 用于治疗诊断的生物标志物
PH12018501083A1 (en) 2010-03-04 2019-02-18 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
RU2598711C2 (ru) 2010-07-22 2016-09-27 Те Риджентс Оф Те Юниверсити Оф Калифорния Антитело к противоопухолевому антигену и способы применения
AU2012228100B2 (en) 2011-03-17 2016-09-08 The University Of Birmingham Re-directed immunotherapy
AU2012216627A1 (en) * 2011-11-14 2013-05-30 Newcastle Innovation Ltd. Composition and methods for the diagnosis, prognosis and treatment of leukemia
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
EP3152235B1 (en) 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
EP3442574A4 (en) 2016-04-15 2019-12-11 MacroGenics, Inc. Novel B7-H3 binding MOLECULES, ANTIBODY-ACTIVE CONJUGATES AND METHOD OF USE THEREOF
WO2018135653A1 (ja) 2017-01-23 2018-07-26 学校法人東洋大学 抗ｅｐｈａ２抗体及びこれを用いたｅｐｈａ２の免疫学的検出
US11459394B2 (en) 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
CN111954682A (zh) * 2018-03-19 2020-11-17 阿贝奥姆公司 针对程序性死亡配体1(pd-l1)的高亲和力中和单克隆抗体及其用途
CA3096222A1 (en) 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
WO2020131697A2 (en) 2018-12-17 2020-06-25 Revitope Limited Twin immune cell engager
US11918649B2 (en) 2019-09-18 2024-03-05 Molecular Templates, Inc. PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds
CN114423793A (zh) 2019-09-18 2022-04-29 分子模板公司 包含志贺菌毒素a亚基支架的pd-l1结合分子
US11807687B2 (en) 2019-10-03 2023-11-07 Atyr Pharma, Inc. Therapeutic compositions comprising anti-NRP2 antibodies
JP7745556B2 (ja) 2020-02-21 2025-09-29 マクロジェニクス，インコーポレーテッド Ｃｄ１３７結合分子及びその使用
EP4262858A1 (en) 2020-12-16 2023-10-25 Molecular Templates, Inc. Clinical methods for use of a pd-l1-binding molecule comprising a shiga toxin effector
EP4301785A4 (en) 2021-03-05 2025-04-23 Atreca, Inc. EPHA2 ANTIBODIES
US20250340655A1 (en) * 2022-05-27 2025-11-06 Taipei Medical University Epha2-targeting antibodies and their applications in cancer treatment
CN116693597B (zh) * 2023-03-09 2024-06-21 南京大学 一种对苯酚衍生物、多肽和蛋白质中酪氨酸进行硝基化的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012172A1 (en) * 1999-08-17 2001-02-22 Purdue Research Foundation Treatment of metastatic disease

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US31252A (en) * 1861-01-29 Improvement in iron ties for cotton-bales
US4472371A (en) * 1979-10-29 1984-09-18 Summa Medical Corporation Radiolabeled antibody to anti-tumor associated antigen and process
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5001225A (en) * 1986-12-08 1991-03-19 Georgetown University Monoclonal antibodies to a pan-malarial antigen
US4885238A (en) * 1987-10-30 1989-12-05 The United States Of America As Represented By The Department Of Health And Human Services Immortalized human bronchial epitherial mesothelial cell lines
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5514554A (en) * 1991-08-22 1996-05-07 Becton Dickinson And Company Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy
EP1291360A1 (en) * 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5955291A (en) * 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5837448A (en) * 1992-05-15 1998-11-17 The Salk Institute For Biological Studies Protein-tyrosine kinase genes
US5824303A (en) * 1992-11-13 1998-10-20 Amgen Inc. Eck receptor ligands
NZ258697A (en) * 1992-11-13 1996-03-26 Immunex Corp Elk-l polypeptide, coding sequence and vector therefor
JPH08505765A (ja) * 1992-11-13 1996-06-25 アムジエン・インコーポレーテツド Ｅｃｋ受容体リガンド
US5811098A (en) * 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5516658A (en) * 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek
US5747033A (en) * 1993-10-28 1998-05-05 Regeneron Pharmaceuticals, Inc. Method of enhancing the biological activity of Eph family ligands
US5457048A (en) * 1993-12-03 1995-10-10 La Jolla Cancer Research Foundation Eph-related tyrosine kinases, nucleotide sequences and methods of use
US5814479A (en) * 1994-01-04 1998-09-29 Zhou; Renping Bsk receptor-like tyrosine kinase
WO1995028484A1 (en) * 1994-04-15 1995-10-26 Amgen Inc. Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases
US5624899A (en) * 1994-07-20 1997-04-29 Genentech Inc. Method for using Htk ligand
US5587459A (en) * 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US5795734A (en) * 1994-09-19 1998-08-18 President And Fellows Of Harvard College EPH receptor ligands, and uses related thereto
US5759775A (en) * 1994-10-27 1998-06-02 Genetech, Inc. Methods for detecting nucleic acids encoding AL--1 neurotrophic factor
US6057124A (en) * 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
US5876949A (en) * 1995-05-31 1999-03-02 The Trustees Of The University Of Pennsylvania Antibodies specific for fragile X related proteins and method of using the same
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US5795775A (en) * 1996-09-26 1998-08-18 Becton Dickinson And Company Culture vessel and assembly
US5761934A (en) * 1996-10-22 1998-06-09 Kuo; Li-Tsao Cable lock and an universal hold-down support
US6387615B2 (en) * 1997-04-11 2002-05-14 Isis Innovation Limited Methods and materials for the diagnosis or prognosis of asthma
WO1999008696A1 (en) * 1997-08-19 1999-02-25 Vanderbilt University METHODS FOR DETERMINING CELL RESPONSES THROUGH EphB RECEPTORS
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
US6864227B1 (en) * 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US6887674B1 (en) * 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US6696550B2 (en) * 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
DK1135153T3 (da) * 1998-11-20 2005-08-15 Genentech Inc Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
JP4948728B2 (ja) * 1999-08-17 2012-06-06 パーデュー・リサーチ・ファウンデーション 癌診断用抗体
US6245320B1 (en) * 1999-09-01 2001-06-12 University Of Maryland Inhibition of mucin release from airway goblet cells by polycationic peptides
WO2001039800A2 (en) * 1999-12-06 2001-06-07 The Board Of Trustees Of The University Of Arkansas Controlled delivery of antigens
EP2289550A3 (en) * 2000-01-27 2012-02-15 MedImmune, LLC Ultra high affinity neutralizing antibodies
DK1259547T3 (da) * 2000-03-01 2012-10-15 Medimmune Inc Højpotente, rekombinante antistoffer og fremgangsmåde til fremstilling heraf
AU2001256970C1 (en) * 2000-03-31 2008-07-03 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6818216B2 (en) * 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US6855493B2 (en) * 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
WO2002102974A2 (en) * 2000-12-08 2002-12-27 Medimmune, Inc. Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
ATE503023T1 (de) * 2001-06-18 2011-04-15 Rosetta Inpharmatics Llc Diagnose und prognose von brustkrebspatientinnen
US20030100497A1 (en) * 2001-06-20 2003-05-29 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
JP2003059182A (ja) * 2001-08-10 2003-02-28 Teac Corp １ビット形式ディジタル信号の記録方法及び記録装置及び付加装置
WO2003094859A2 (en) * 2002-05-10 2003-11-20 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
EP1575509B1 (en) * 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
TW200501985A (en) * 2002-07-25 2005-01-16 Medimmune Inc Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
US7504211B2 (en) * 2002-08-27 2009-03-17 Bristol-Myers Squibb Company Methods of using EPHA2 for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells
WO2004028551A1 (en) * 2002-09-24 2004-04-08 The Burnham Institute Novel agents that modulate eph receptor activity
JP2006524693A (ja) * 2003-04-11 2006-11-02 メディミューン，インコーポレーテッド ＥｐｈＡ２および非腫瘍性過増殖性細胞障害
JP4764818B2 (ja) * 2003-04-11 2011-09-07 メディミューン，エルエルシー 組換えｉｌ−９抗体およびその使用
EP1617805A4 (en) * 2003-04-11 2012-07-04 Medimmune Llc METHODS FOR PREVENTING OR TREATING RESPIRATORY CONDITIONS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012172A1 (en) * 1999-08-17 2001-02-22 Purdue Research Foundation Treatment of metastatic disease

Also Published As

Publication number Publication date
WO2003094859A3 (en) 2005-02-03
AU2009202542A1 (en) 2009-07-16
AU2003243228A1 (en) 2003-11-11
US20040028685A1 (en) 2004-02-12
JP4557714B2 (ja) 2010-10-06
EP1519956B1 (en) 2011-09-21
EP1519956A4 (en) 2006-10-25
JP2005538701A (ja) 2005-12-22
CA2485373A1 (en) 2003-11-20
EP1519956A2 (en) 2005-04-06
JP2010246546A (ja) 2010-11-04
ATE525398T1 (de) 2011-10-15
US20100278838A1 (en) 2010-11-04
ES2373715T3 (es) 2012-02-08
US20070166314A1 (en) 2007-07-19
WO2003094859A2 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
AU2003243228B2 (en) EphA2 monoclonal antibodies and methods of use thereof
EP1575509B1 (en) Epha2 agonistic monoclonal antibodies and methods of use thereof
US7604799B2 (en) EphA4 Antibodies
AU2004293034B2 (en) EphA2 agonistic monoclonal antibodies and methods of use thereof
US20100143345A1 (en) Epha2 agonistic monoclonal antibodies and methods of use thereof
US20090220527A1 (en) Affinity optimized epha2 agonistic antibodies and methods of use thereof
WO2005016381A2 (en) Combination therapy for the treatment and prevention of cancer using epha2, pcdgf, and haah
AU2012202569A1 (en) EPHA2 agonistic monoclonal antibodies and methods of use thereof

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 18, NO 2, PAGE(S) 548 UNDER THE HEADING APPLICATIONS OPI NAME INDEX UNDER THE NAME MEDIMMUNE, LLC, INC., APPLICATION NO. 2003243228, UNDER INID (43) CORRECT THE PUBLICATION DATE TO READ 24 NOVEMBER 2003.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired